Hormone replacement therapy remains a debated topic in osteoporosis care, and that debate was spotlighted at AACE 2026 in Las Vegas. In a Medscape transcript edited for clarity, endocrinologists Dr Kaniksha Desai of Stanford and Dr Ejigayehu Abate discussed the role of HRT in patients with osteoporosis.
The conversation centers on why HRT continues to generate controversy even as clinicians look for effective ways to protect bone health. Rather than presenting the issue as settled, the discussion frames HRT as a treatment area that still requires careful judgment in real-world practice.
A key theme is how doctors think through where hormone therapy may or may not fit within an osteoporosis treatment plan. The topic raises broader questions about patient selection, competing considerations in care, and how specialists approach decisions when treatment options are not straightforward.
The exchange reflects a larger trend in endocrinology: osteoporosis treatment is increasingly individualized, and hormone therapy remains one of the most closely examined options in that process. For clinicians, the discussion highlights that HRT in osteoporosis is still an area where nuance matters.
